| Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). | |
| | |
MedLine Citation:
|
PMID: 11274933 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite scientific evidence that secondary prevention medical therapies reduce mortality in patients with established coronary artery disease, these therapies continue to be underutilized in patients receiving conventional care. To address this issue, a Cardiac Hospital Atherosclerosis Management Program (CHAMP) focused on initiation of aspirin, cholesterol-lowering medication (hydroxymethylglutaryl coenzyme A [HMG CoA] reductase inhibitor titrated to achieve low-density lipoprotein [LDL] cholesterol < or =100 mg/dl), beta blocker, and angiotensin-converting enzyme (ACE) inhibitor therapy in conjunction with diet and exercise counseling before hospital discharge in patients with established coronary artery disease. Treatment rates and clinical outcome were compared in patients discharged after myocardial infarction in the 2-year period before (1992 to 1993) and the 2-year period after (1994 to 1995) CHAMP was implemented. In the pre- and post-CHAMP patient groups, aspirin use at discharge improved from 68% to 92% (p <0.01), beta blocker use improved from 12% to 62% (p <0.01), ACE inhibitor use increased from 6% to 58% (p <0.01), and statin use increased from 6% to 86% (p <0.01). This increased use of treatment persisted during subsequent follow-up. There was also a significant increase in patients achieving a LDL cholesterol < or =100 mg/dl (6% vs 58%, p <0.001) and a reduction in recurrent myocardial infarction and 1-year mortality. Compared with conventional guidelines and care, CHAMP was associated with a significant increase in use of medications that have been previously demonstrated to reduce mortality; more patients achieved an LDL cholesterol < or =100 mg/dl, and there were improved clinical outcomes in patients after hospitalization for acute myocardial infarction. |
| | |
Authors:
|
G C Fonarow; A Gawlinski; S Moughrabi; J H Tillisch |
Related Documents
:
|
2222103 - Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. 7841023 - Structural studies of nmr detected lipids in myocardial ischemia. 9731603 - Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primar... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of cardiology Volume: 87 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2001 Apr |
Date Detail:
|
Created Date: 2001-03-29 Completed Date: 2002-01-17 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 819-22 Citation Subset: AIM; IM |
Affiliation:
|
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, Department of Medicine, Los Angeles, California, USA. gfonarow@mednet.ucla.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
administration & dosage,
therapeutic use Aged Angiotensin-Converting Enzyme Inhibitors / administration & dosage, therapeutic use Antilipemic Agents / administration & dosage, therapeutic use Aspirin / administration & dosage, therapeutic use Cholesterol, LDL / blood Cohort Studies Coronary Artery Disease / prevention & control* Diet Disease Management* Exercise Female Hospitalization* Hospitals, University Humans Los Angeles Male Myocardial Infarction / prevention & control* Patient Compliance* Patient Education as Topic Preventive Health Services / standards* Program Evaluation Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antilipemic Agents; 0/Cholesterol, LDL; 50-78-2/Aspirin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The expanding world of co-stimulation: the two-signal model revisited.
Next Document: Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after...